Nemaura Med Inc (NMRD) 1.9000 $NMRD
Nemaura Medical Inc., completes second FDA Pre-submission meeting and appoints Navigant to submit IDE for Nemaura's sugarBEAT(R) system
BusinessWire - Thu Aug 04, 6:50AM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT(R), today announced that it recently held a second pre-submission meeting with the FDA to discuss the clinical program for its sugarBEAT(R) system, for the purpose of a PMA submission in the USA. As a result of its meeting, Nemaura's management has determined a clear direction for the clinical program and has appointed Navigant (NYSE: NCI) to develop the Investigational Device Exemption (IDE) application to submit to the FDA for approval, prior to commencement of the clinical program.
NCI: 19.71 (+0.32)
Interim Clinical Data on Increased Measurement Frequency for sugarBEAT(R) CGM Released by Nemaura Medical.
BusinessWire - Thu Apr 14, 12:50PM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura" , a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT(R), today announced further interim clinical data based on increased measurement frequency.
Nemaura Medical Announces receipt of notification of CE Approval for its sugarBEAT(R) Continuous Glucose Monitoring System
BusinessWire - Tue Mar 15, 8:19AM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura" , a medical device company developing a minimally invasive wireless continuous glucose monitoring ("CGM" system known as sugarBEAT(R), announced today that it has received notification of CE Approval for its sugarBEAT(R) system from its European Notified Body. The device for which CE grant notice has been approved was used in a 160 patient day study generating over 1500 paired data points, and retrospective evaluation of the glucose data. Nemaura expects the CE certificate to be received in April, upon completion of its 3-yearly ISO13485 Quality Systems recertification process, for which it was audited at the end of February 2016.
Nemaura Medical Announces Joint Venture for European Launch of sugarBEAT(R) System
BusinessWire - Wed Dec 02, 8:06AM CST
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura" , a medical device company developing a minimally invasive wireless continuous glucose monitoring ("CGM" system known as sugarBEAT(R), announced today that it has entered into an equal Joint Venture agreement with DBJ Jersey to market the sugarBEAT(R) system in Europe.
Nemaura Medical Announces Filing of Application for FDA Pre-Submission Program for sugarBEAT(R) System
BusinessWire - Tue Oct 13, 12:00PM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura" , a medical device company developing a minimally invasive wireless CGM (Continuous Glucose Monitoring) system known as sugarBEAT(R), announced today that it has submitted an application under the FDA Pre-submission Program to confirm the Classification of their CGM for the US market.
Nemaura Medical Present Positive Interim Clinical Trial Results of Its sugarBEAT(R) System
BusinessWire - Fri Oct 02, 12:19PM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura" , a medical device company developing the sugarBEAT(R) CGM System as a minimally invasive, wireless continuous glucose monitoring system, announced today that it has conducted a further interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients, and have determined a reduction in MARD from 18% to less than 11.8%. MARD is the Mean Absolute Relative Difference between finger-stick measurements and CGM sensor glucose values. A lower MARD indicates higher accuracy.
Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT(R) System at the Marcum Microcap Conference, New York
BusinessWire - Wed May 27, 7:00AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura" , a medical device company developing the sugarBEAT(R) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015.
Nemaura Medical to Present at the 2015 Marcum Microcap Conference May 28
BusinessWire - Tue May 19, 11:22AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), a leading developer of minimally-invasive transdermal diagnostic technologies, announced today that Dr. D F Chowdhury, CEO, and Bashir Timol, Commercial Director, will be presenting at the 2015 Marcum Microcap Conference, which will take place May 27th to May 28th at the Grand Hyatt Hotel in New York City.
Global Blood Glucose Meters Pipeline Review 2015
M2 - Tue Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhqtk3/blood_glucose) has announced the addition of the "Blood Glucose Meters - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key blood glucose meters pipeline products. Scope: - Extensive coverage of the Blood Glucose Meters products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Blood Glucose Meters and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Blood Glucose Meters under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured - Partial List - C8 MediSensors, Inc. - GlucoSet AS - Glucovation, Inc. - GluMetrics, Inc. - GluSense Ltd. - GlySens Incorporated - GlySure Ltd - Grove Instruments Inc. - Hygiena, LLC - Hypo-Safe A/S - Mendor Oy - MicroCHIPS, Inc. - mobiLIFE - Nagasaki University - Nemaura Medical Inc - Newton Photonics Inc - Northwestern University - NovioSense B.V. - Optiscan Biomedical Corporation - Pepex Biomedical, Inc. - Pignolo SpA - PositiveID Corporation - Quick, LLC - Senseonics, Incorporated - Sentec Ag - Senzime AB - Socrates Health Solutions, Inc. - University of Western Ontario - Vytrace, Inc. - Xhale, Inc. For more information visit http://www.researchandmarkets.com/research/vh...od_glucose
Nemaura Medical Inc., completes second FDA Pre-submission meeting and appoints Navigant to submit IDE for Nemaura's sugarBEAT(R) system
BusinessWire - Thu Aug 04, 6:50AM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT(R), today announced that it recently held a second pre-submission meeting with the FDA to discuss the clinical program for its sugarBEAT(R) system, for the purpose of a PMA submission in the USA. As a result of its meeting, Nemaura's management has determined a clear direction for the clinical program and has appointed Navigant (NYSE: NCI) to develop the Investigational Device Exemption (IDE) application to submit to the FDA for approval, prior to commencement of the clinical program. NCI: 19.71 (+0.32)
Interim Clinical Data on Increased Measurement Frequency for sugarBEAT(R) CGM Released by Nemaura Medical.
BusinessWire - Thu Apr 14, 12:50PM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive, needle-free, wireless CGM (Continuous Glucose Monitoring) patch known as sugarBEAT(R), today announced further interim clinical data based on increased measurement frequency. Nemaura Medical Announces receipt of notification of CE Approval for its sugarBEAT(R) Continuous Glucose Monitoring System
BusinessWire - Tue Mar 15, 8:19AM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive wireless continuous glucose monitoring ("CGM" system known as sugarBEAT(R), announced today that it has received notification of CE Approval for its sugarBEAT(R) system from its European Notified Body. The device for which CE grant notice has been approved was used in a 160 patient day study generating over 1500 paired data points, and retrospective evaluation of the glucose data. Nemaura expects the CE certificate to be received in April, upon completion of its 3-yearly ISO13485 Quality Systems recertification process, for which it was audited at the end of February 2016. Nemaura Medical Announces Joint Venture for European Launch of sugarBEAT(R) System
BusinessWire - Wed Dec 02, 8:06AM CST
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive wireless continuous glucose monitoring ("CGM" system known as sugarBEAT(R), announced today that it has entered into an equal Joint Venture agreement with DBJ Jersey to market the sugarBEAT(R) system in Europe. Nemaura Medical Announces Filing of Application for FDA Pre-Submission Program for sugarBEAT(R) System
BusinessWire - Tue Oct 13, 12:00PM CDT
Nemaura Medical Inc. (OTC BB: NMRD),("Nemaura"
, a medical device company developing a minimally invasive wireless CGM (Continuous Glucose Monitoring) system known as sugarBEAT(R), announced today that it has submitted an application under the FDA Pre-submission Program to confirm the Classification of their CGM for the US market. Nemaura Medical Present Positive Interim Clinical Trial Results of Its sugarBEAT(R) System
BusinessWire - Fri Oct 02, 12:19PM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"
, a medical device company developing the sugarBEAT(R) CGM System as a minimally invasive, wireless continuous glucose monitoring system, announced today that it has conducted a further interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients, and have determined a reduction in MARD from 18% to less than 11.8%. MARD is the Mean Absolute Relative Difference between finger-stick measurements and CGM sensor glucose values. A lower MARD indicates higher accuracy. Nemaura Medical to Present Positive Interim Clinical Trial Results of its sugarBEAT(R) System at the Marcum Microcap Conference, New York
BusinessWire - Wed May 27, 7:00AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), ("Nemaura"
, a medical device company developing the sugarBEAT(R) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced today that it has conducted an interim analysis of clinical data from its ongoing 540 patient day clinical program of Type I and Type II diabetic Patients. Nemaura will present these findings at the Marcum Microcap Conference in New York on Thursday 28th May 2015. Nemaura Medical to Present at the 2015 Marcum Microcap Conference May 28
BusinessWire - Tue May 19, 11:22AM CDT
Nemaura Medical Inc. (OTC BB: NMRD), a leading developer of minimally-invasive transdermal diagnostic technologies, announced today that Dr. D F Chowdhury, CEO, and Bashir Timol, Commercial Director, will be presenting at the 2015 Marcum Microcap Conference, which will take place May 27th to May 28th at the Grand Hyatt Hotel in New York City.
Global Blood Glucose Meters Pipeline Review 2015
M2 - Tue Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhqtk3/blood_glucose) has announced the addition of the "Blood Glucose Meters - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key blood glucose meters pipeline products. Scope: - Extensive coverage of the Blood Glucose Meters products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Blood Glucose Meters and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Blood Glucose Meters under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured - Partial List - C8 MediSensors, Inc. - GlucoSet AS - Glucovation, Inc. - GluMetrics, Inc. - GluSense Ltd. - GlySens Incorporated - GlySure Ltd - Grove Instruments Inc. - Hygiena, LLC - Hypo-Safe A/S - Mendor Oy - MicroCHIPS, Inc. - mobiLIFE - Nagasaki University - Nemaura Medical Inc - Newton Photonics Inc - Northwestern University - NovioSense B.V. - Optiscan Biomedical Corporation - Pepex Biomedical, Inc. - Pignolo SpA - PositiveID Corporation - Quick, LLC - Senseonics, Incorporated - Sentec Ag - Senzime AB - Socrates Health Solutions, Inc. - University of Western Ontario - Vytrace, Inc. - Xhale, Inc. For more information visit http://www.researchandmarkets.com/research/vh...od_glucose
